Work

Population pharmacokinetic analysis of raludotatug deruxtecan (R-DXd), a cadherin 6 (CDH6)–directed antibody–drug conjugate (ADC), in patients (pts) with advanced ovarian cancer (OC) or renal cell carcinoma (RCC).

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.5571

Authors: Felipe K. Hurtado, Emily Schapiro, Jonah Lyon, Nicoletta Colombo, Sabrina Chiara Cecere, Kosei Hasegawa, Alexander Philipovskiy, Izna Ali, Youngjun Yoo, Hiroyuki Inoue, Yvonne Lau

Institutions: Daiichi Sankyo (United States), European Institute of Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Saitama International Medical Center, Saitama Medical University, Florida Cancer Specialists & Research Institute, Daiichi-Sankyo (Japan)

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Daiichi Sankyo Europe

OpenAlex ID: W7162520135

Cites:

Cited by:

Related to: